Evaluating a protein as a marker for liver cancer recurrence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to determine if elevated levels of a specific protein can indicate the recurrence of liver cancer. It will compare 50 recurrent liver cancer patients with 250 additional recurrent liver cancer patients to assess the protein's levels against those of primary liver cancer patients. The study will collect clinical data, including demographics and medical history, while implementing strict quality control measures to ensure data reliability. Participants will provide blood samples for analysis, and the study has received ethical approval.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with primary hepatocellular carcinoma or diagnosed with non-HCC
* The patient or the patient's legal representative must be able to read, understand, and sign the informed consent form
* Agree to provide blood samples and have good clinical compliance
* Complete clinical basic information, including: the patient's unique traceability number (ID card number/outpatient number/health insurance card number), age, gender, imaging and/or pathological diagnosis results (for patients with primary liver disease), imaging examination confirmed heteromorphic liver cancer (for non-HCC patients)

Exclusion Criteria:

* Pregnant women
* Those who have received organ transplantation
* Non-HCC patients diagnosed with other tumors
* Patients with primary hepatocellular carcinoma complicated by other tumors
* Those judged by the researcher as not meeting the inclusion criteria

Where it's running

• The Second Affiliated Hospital of Nanjing Medical University
  Nanjing, Jiangsu, China Recruiting

Study contacts

• Study coordinator: zhang yewei, doctor
• Email: zhangyewei@njmu.edu.cn
• Phone: +86 13813885788

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Plasma methylation test for detecting liver cancer recurrence (GNB4 and Riplet)

  This test sees if a blood-based methylation assay measuring GNB4 and Riplet can detect return of primary liver cancer in people who had hepatectomy, liver transplant, ablation, or TACE.

  Recruiting Wuhan Ammunition Life-tech Co., Ltd · Wuhan, Hubei · NCT07466602

• Using contrast-enhanced ultrasound to check Y-90 radioembolization response in liver cancer

  This will test whether contrast-enhanced ultrasound (CEUS) can show treatment response to Y‑90 radioembolization in people with newly diagnosed hepatocellular carcinoma who are scheduled for TARE.

  Recruiting Phase 2 Thomas Jefferson University · Philadelphia, Pennsylvania · NCT07145801

• Combining advanced ultrasound and molecular analyses to map tumor differences in liver cancer

  This project tries combining multiple ultrasound techniques with molecular (multi-omics) tests to see if they can better characterize tumors and guide care for adults with primary liver cancer who are scheduled for surgery.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07101237

• Combining portal and hepatic vein embolization for liver cancer treatment

  This study is testing if combining two types of vein treatments can help more people with liver cancer have surgery and live longer.

  Recruiting Maastricht University · New Haven, Connecticut and 54 other locations · NCT06914648

• Comparing two treatments for inoperable primary liver cancer

  This study is testing which treatment works better for people with inoperable primary liver cancer by comparing stereotactic radiosurgery and radiofrequency ablation.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT06766643

• Evaluation of the HistoSonics Edison System for treating liver tumors

  This study is testing how well the HistoSonics Edison System works for treating liver tumors and how different factors affect the treatment's success in real patients.

  Recruiting at 32 sites HistoSonics, Inc. · Mobile, Alabama and 34 other locations · NCT06486454

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.